Dysregulated metabolism underlies many of the leading causes of mortality and morbidity in the US including cardiometabolic diseases. Metabolomics studies can identify novel disease biomarkers, novel therapeutic targets, and biological pathways with pathological relevance. Emerging technologies in metabolomics allow the interrogation of large numbers of metabolites from diverse pathways. However, these approaches remain expensive and time-consuming. Applying metabolomics to very large cohorts of individuals to conduct epidemiological studies is not feasible, due to the practical challenges and costs of implementing these assays at scale. These challenges have limited discovery of novel biomarker-disease associations. We propose to address these limitations with a genetics-based ?virtual? metabolite study design that will allow us to define genetic predictors of metabolite concentrations in a small population in whom the metabolite was measured, and then use these genetic predictors to impute metabolite concentrations in a large population in whom the metabolite was not measured. This approach vastly amplifies the sample size for discovery, and can rapidly identify novel biomarkers for downstream validation. The primary aims of this proposal are to: 1) construct single nucleotide polymorphism (SNP)-based predictors of circulating metabolites, and identify associations with cardiometabolic phenotypes, including type 2 diabetes and coronary artery disease; 2) validate the associations with direct metabolite measurements; 3) identify pleiotropic associations between metabolite genetic predictors and the clinical phenome. These analyses are enabled by genetic approaches that allow us to integrate data from large scale genome-wide association studies (GWAS) of cardiometabolic diseases and a collection of electronic health record linked-DNA biobanks comprising over 700,000 subjects. Innovative features of this approach include the efficiency and scale of the analysis, inclusion of under-represented and vulnerable populations and implementation of a re-usable and scalable analytical framework that will accelerate biomarker discovery and implementation. Upon completion of this project, we will construct a publicly accessible online resource of metabolite-disease associations that will be available to researchers as a source for both hypothesis testing and generation. Ultimately, these studies will advance the field of metabolomics by rapidly advancing the process of linking metabolites to clinically-relevant diseases.

Public Health Relevance

Cardiometabolic diseases such as diabetes and coronary artery disease can be caused by abnormalities in metabolite levels. Identifying metabolites that are measurable in blood samples will lead to improved and individualized diagnostic, prevention and treatment strategies for these diseases. We will use genetic approaches to identify novel blood metabolites associated with cardiometabolic diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL142856-01A1
Application #
9735719
Study Section
Clinical and Integrative Cardiovascular Sciences Study Section (CICS)
Program Officer
Srinivas, Pothur R
Project Start
2019-04-01
Project End
2024-03-31
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
1
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232